Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Xintela. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Xintela's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Xintela has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Xintela's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Xintela's earnings growth to the Germany market average as no estimate data is available.
Unable to compare Xintela's revenue growth to the Germany market average as no estimate data is available.
Unable to determine if Xintela is high growth as no earnings estimate data is available.
Unable to determine if Xintela is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Xintela's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Evy Lundgren-Åkerlund, BSc, Ph.D, Assoc Prof, has been the Chief Executive Officer of Xintela AB (publ) since 2009. Dr. Lundgren-Åkerlund co-founded Cartela AB in 2000 and served as its Managing Director. She was with Cartela AB from 2000 to 2007 as Chief Executive Officer and Research Director. She served as the Chief Executive Officer at Ideon Bioincubator/Lund Life Science Incubator from 2008 to 2012. She has extensive scientific experience in cell- and matrix-biology and leadership experience from both academia and the biotech industry. Dr. Lundgren-Åkerlund started her career as postdoctoral at UCSD. In 1990, She joined Lund University as a Research Associate and in 1993 she became an Associate Professor. Her research on integrins in cartilage led to the discovery of the integrin a10b1, which is the focus of Cartela AB's research and development. She served as Director at Xintela AB. She served as a Director of Ideon Bioincubator/Lund Life Science Incubator from 2008 to 2012. She was appointed Associate Professor at Lund University in 1994. Dr. Lundgren-Åkerlund received her a BSc degree in Biomedical Sciences and a PhD in Medical and Physiological Chemistry from Uppsala University in 1987.
Evy's compensation has increased whilst company is loss making.
Evy's remuneration is about average for companies of similar size in Germany.
Chairman of the Board & Strategic Advisor
Chief Executive Officer
COO, Chief Medical Officer & Director
CFO & Finance Director
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Xintela board of directors is about average.
Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. It develops products based on XINMARK, a patented marker technology that identifies and selects a range of stem cells, which can develop cartilage cells. The company is developing stem cell-based products for the treatment of patients with traumatic cartilage damage or early osteoarthritis; cartilage damage in horses; brain tumors; and cancer. It is also developing XACT, an analytical test for cell therapy. Xintela AB (publ) has a co-development agreement with Redwood Bioscience Inc. to jointly develop an antibody-drug conjugate therapeutic product with a focus on glioblastoma, a form of brain tumor in adults. The company was founded in 2009 and is based in Lund, Sweden.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.